Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03979066
Title Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gulam Manji
Indications

pancreatic ductal adenocarcinoma

Therapies

Atezolizumab

Atezolizumab + PEGPH20

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.